In‐vitro assays of polymer‐coated stents eluting platelet glycoprotein IIb/IIIa receptor monoclonal antibody

Abstract

AbstractThe monoclonal antibody (mAb) to the platelet glycoprotein (GP) IIb/IIIa receptor has potent antiplatelet and antithrombotic characteristics shown to reduce thrombus‐related major complications after coronary angioplasty. This mAb can be incorporated in drug‐eluting stents capable of releasing single or multiple bioactive agents into the bloodstream and surrounding tissues. Stents eluting the monoclonal mouse anti‐human platelet glycoprotein IIb/IIIa antibody SZ‐262 were tested for their effectiveness in improving the blood compatibility and the antithrombotic characteristics by immunofluorescence and scanning electron microscopy (SEM). The SEM results convincingly demonstrated that the surface of the mAb eluting‐stents was completely free of platelet uptake without any sign of cellular debris or proteinaceous deposits, compared with controls. The deformation index of platelets on the l‐polylactic acid (l‐PLA) coated stents were higher than bare Nitinol intravascular stents, as shown by SEM images. Monoclonal antibody to the platelet GP IIb/IIIa receptor, when eluting from l‐PLA polymer‐coated stents, effectively inhibits platelet aggregation in the stent microenvironment, thus demonstrating a potential capacity of reducing thrombosis, improving blood flow and arterial patency rates, and inhibiting cyclic blood flow variations. These results highlight the possibility of such monoclonal antibody‐eluting stents to reduce or possibly eliminate thrombosis and in‐stent restenosis. © 2007 Wiley Periodicals, Inc. J Biomed Mater Res, 2007